Lonza to make trial stocks of Micromet cancer MAb

By Staff Reporter

- Last updated on GMT

Related tags Leukemia

Lonza will produce trial supplies of Micromet’s candidate blood cancer treatment blinatumomab under a contract announced today.

The Swiss contractor will undertake process development and manufacturing of the monoclonal antibody (MAb), which is in trials for both acute lymphoblastic leukemia and non-Hodgkin’s lymphoma.

Maryland, US headquartered Micromet can also ask Lonza to develop commercial-scale manufacturing processes for the antibody if it goes on to gain regulatory approval.

Micromet, which reacquired rights to commericalise blinatumomab from AstraZeneca’s MedImmune arm earlier this month, developed the MAb using its BiTE development platform.

The technology, which stimulates the body's cytotoxic, or cell-destroying, T cells against tumor cells, is also the subject of collaborations with Bayer Schering Pharma, Nycomed and Merck Serono.

Most recently Micromet signed a $475m deal with French drugmaker Sanofi-Aventis that will see the US developer use its technology to develop another anticancer antibody through to Phase II clinical trials.

At the time Sanofi's senior VP of R&D, Marc Cluzel, said: “Micromet's BiTE antibodies represent a promising new approach to treating cancer," adding that “we believe [they] have the potential to significantly expand the treatment options that we can offer to cancer patients in the future​."

Lonza biomanufacturing

Earlier this month Lonza’s biomanufacturing arm won another MAb deal signing with GlaxoSmithKline (GSK) and Genmab’s to make Arzerra (ofatumumab) on a commercial-scale.

Arzerra, which was recently approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukemia (CLL), was described as a “key biopharmaceutical for both [GSK and Genmab],” ​by Lonza COO Stephan Kutzer.

That deal, coupled with the new Micromet accord, may indicate that Lonza’s biomanufacturing arm is emerging as one of the “go to” contract manufacturing solutions for the large-scale production of biologics.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more